Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 48: 307-314, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (17)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by von Bonsdorff, L.
Right arrow Articles by Parkkinen, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by von Bonsdorff, L.
Right arrow Articles by Parkkinen, J.
Related Collections
Right arrow Nutrition
Right arrow Hematology
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2002;48:307-314.)
© 2002 American Association for Clinical Chemistry, Inc.

Bleomycin-detectable Iron Assay for Non-Transferrin-bound Iron in Hematologic Malignancies

Leni von Bonsdorff1a, Enni Lindeberg1, Leila Sahlstedt2, Jari Lehto3 and Jaakko Parkkinen1

1 Finnish Red Cross Blood Transfusion Service, Kivihaantie 7, FIN-00310 Helsinki, Finland.

2 Department of Medicine, PO Box 340, Helsinki University Central Hospital, FIN-00029 Helsinki, Finland.

3 Department of Public Health, PO Box 41, University of Helsinki, FIN-00014 Helsinki, Finland.

aAuthor for correspondence. Fax 358-9-5801429; e-mail leni.bonsdorff{at}bts.redcross.fi.

Background: A microwell modification of the bleomycin assay for determining non-transferrin-bound iron (NTBI) was evaluated and compared with a chelation method.

Methods: The bleomycin assay reagent and sample volumes were halved, and measurements were done in microwell plates. Samples from patients treated for hematologic malignancies were studied. The chelation method was based on mobilization of NTBI with a chelator and measurement of the ultrafiltered iron-chelator complex. NTBI results were also compared with transferrin saturation and the distribution of transferrin iron forms by urea-polyacrylamide gel electrophoresis.

Results: The bleomycin assay intraassay imprecision (CV) was 7.7% and 8.2% and the interassay imprecision was 18% and 9.8% for a low (0.2 µmol/L) and a high (1.5 µmol/L) control, respectively. Hemolysis increased measured NTBI. A detection limit of 0.1 µmol/L was established based on the interference of nonvisible hemolysis and on accuracy studies. In patient samples, NTBI exceeded the detection limits only when transferrin saturation was >80%. Compared with the chelation method, the bleomycin assay gave clearly lower NTBI concentrations. The chelation method also gave positive results at <80% transferrin saturation. The recovery of iron added as ferric nitrilotriacetate to serum was 33% by the bleomycin assay and 64% by the chelation assay.

Conclusions: The microwell version of the bleomycin assay is reproducible. When hemolyzed samples were excluded, bleomycin-detectable iron was found only when the transferrin saturation was >80%, suggesting high specificity. Bleomycin-detectable iron constitutes only a portion of the NTBI measured by the chelation method.




The following articles in journals at HighWire Press have cited this article:


Home page
J. Am. Soc. Nephrol.Home page
D. B. Van Wyck
Labile Iron: Manifestations and Clinical Implications
J. Am. Soc. Nephrol., December 1, 2004; 15(suppl_2): S107 - S111.
[Full Text] [PDF]


Home page
BloodHome page
S. G. Gehrke, H. Kulaksiz, T. Herrmann, H.-D. Riedel, K. Bents, C. Veltkamp, and W. Stremmel
Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron
Blood, July 1, 2003; 102(1): 371 - 376.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.